FDA
-
-
-
-
-
-
-
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
-
-
-
-
-
-
-
Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children
-
-
-
-
-
-
-
FDA Schedules Pre-License Inspection of Remestemcel-L Manufacturing
-
-
-
-
-
-
-
Mesoblast Resubmits Biologic License Application (BLA) to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)
-
-
-
-
-
-
-
Jane Bell Joins Mesoblast Board
-
-
-
-
-
-
-
Mesoblast Appoints Dr. Eric Rose as Chief Medical Officer
-
-
-
-
-
-
-
Late Breaking Presentation at American Heart Association Annual Meeting of Landmark Phase 3 Trial of Rexlemestrocel-L in Chronic Heart Failure
-
251,875 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All